Cessation Therapeutics, Inc.
San Jose, CA
- UEI
- J4SMPV2JMR25
- CAGE
- 84R03
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- Plaza West, 3031 Tisch Way #110, San Jose, CA 95128, USA
- Website
- cessationtherapeutics.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog… | National Institute on Drug Abuse | $7,315,363 | |
| Process development, manufacturing, and preclinical evaluation of a monoclonal antibody for fentanyl overdose | National Institute on Drug Abuse | $9,174,501 | |
| Development of therapeutic anti-nicotine monoclonal antibodies through trivalent vaccine design | National Institute on Drug Abuse | $209,515 |
About Cessation Therapeutics, Inc.
Cessation Therapeutics, Inc. is a for-profit company focused on developing novel antibody therapies to prevent and reverse overdoses related to fentanyl and fentanyl analogs. Through federal grants, Cessation Therapeutics provides research and development services related to monoclonal antibody therapies.
Cessation Therapeutics has received one prime federal grant award and three federal sub-grant awards to support the development of monoclonal antibody treatments. The $9.1 million prime award from the National Institutes of Health supported process development, manufacturing, and preclinical evaluation of an anti-fentanyl monoclonal antibody. The sub-awards supported manufacturing and preclinical research related to monoclonal antibodies for fentanyl and nicotine overdose, in collaboration with partners such as Scripps Research Institute. Specifically, the sub-awards funded formulation, manufacturing, analytical, and regulatory work on monoclonal antibodies, as well as support for preclinical studies in animal models. In summary, Cessation Therapeutics specializes in developing monoclonal antibody therapies for overdose treatment through federal grant programs, providing R&D services with both prime and sub-awards from agencies including NIH and partners such as research institutions.
Quick answers
What is Cessation Therapeutics, Inc.'s UEI?
Cessation Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is J4SMPV2JMR25.
What is Cessation Therapeutics, Inc.'s CAGE code?
Cessation Therapeutics, Inc.'s CAGE code is 84R03.
Where is Cessation Therapeutics, Inc. located?
Cessation Therapeutics, Inc.'s physical address in SAM.gov is Plaza West, 3031 Tisch Way #110, San Jose, CA 95128, USA.
Is Cessation Therapeutics, Inc. registered in SAM.gov?
Yes. Cessation Therapeutics, Inc.'s SAM.gov registration is active through June 3, 2027.
What is Cessation Therapeutics, Inc.'s most recent federal award?
Cessation Therapeutics, Inc.'s most recent federal grant award is Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog… (U01DA063352), from National Institute on Drug Abuse, on September 15, 2025.
On GovTribe
See Cessation Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors